Clinical operations

Lilly’s Enrollment Ranking: Why the Recruitment Denominator Matters

Why Lilly’s enrollment lead needs context: disease mix, primary-outcome follow-up, site-month denominators and practical implications for oncology trial teams.

By Lampgen Clinical Research

Before adding sites, check the clock. A proposed operational measure divides newly enrolled participants by the total months sites were open to recruitment. An enrollment pathway connects referral, screening and enrollment. Supporting copy calls for including zero-enrolling open sites and defining each milestone consistently.
Original explanatory diagram. The recruitment formula is Lampgen’s proposed operational measure; it is not Bond Health’s published metric or an observed study result.
1.90×1.54×
Ratios of Lilly’s reported metric to Novo Nordisk’s: overall non-cancer trials, then the diabetes/obesity subset. Calculated from attributed rounded values; these are not causal estimates of recruitment speed.

What the source reported

A sponsor-level enrollment ranking can help teams ask better feasibility questions, but it cannot establish which company recruits patients fastest unless the measurement captures the relevant recruitment period. Bond Health’s November 2026 analysis, shown in the supplied LinkedIn screenshots, divides actual enrollment by listed sites and by months from study start to primary completion. The resulting metric combines enrollment, site footprint and primary-outcome duration. It should be interpreted as a descriptive study-level comparison. [1, 2]

The screenshots describe finished, company-led Phase 3 trials with at least one U.S. site, a five-year selection window presented as 2021–2026, and a minimum of 15 trials per company. Participant and site counts are worldwide. The company value is the median of trial-level metrics. Cancer trials are excluded. We reviewed the supplied figures and methodology, but did not obtain the underlying NCT list, extraction code or a reproducible registry snapshot. The reported sponsor values remain attributed to Bond Health. [1]

What changes when the disease mix narrows

The reported overall values are 0.40 patients per site per month for Lilly and 0.21 for Novo Nordisk. Dividing those rounded values gives approximately 1.90. Within diabetes and obesity, the screenshots report 0.40 and 0.26, giving approximately 1.54. This narrower comparison preserves Lilly’s lead while reducing the relative gap. [1]

Diabetes and obesity account for 31 of 36 Lilly trials and 38 of 41 Novo Nordisk trials in the supplied analysis. These proportions make the subset relevant, but restricting disease categories does not fully adjust for eligibility, geography, treatment allocation, study design, follow-up or site activation. Ratios of sponsor medians also do not describe a typical individual site. [1]

Primary completion is a different milestone from the end of recruitment

ClinicalTrials.gov ties the actual study start to the first participant’s enrollment. Primary completion is tied to the final collection of primary-outcome data. A study can stop recruiting and continue treatment or outcome follow-up before reaching that date. Using the full interval therefore measures more than the recruitment window. [2]

As an arithmetic implication, a longer primary-outcome interval lowers this metric when enrollment and listed site count stay constant. The same enrollment process could produce a lower value simply because the endpoint requires more follow-up. This is our interpretation of the formula; it is not evidence that follow-up explains Lilly’s observed lead.

The wording “with U.S. sites” also deserves care. It selects studies that include the United States, while the analysis uses global participant and site counts. The chart does not measure U.S.-only site performance. The supplied description does not establish when each listed site actually began or stopped recruitment. [1]

What an operational recruitment measure could add

For a current study, Lampgen proposes reviewing newly enrolled participants per total site-months actually open to recruitment during a defined observation window. Add the eligible recruitment exposure across sites, retain open sites with zero enrollment, and account for documented pauses and closures. This is a proposed operational measure, not the published Bond Health method or a regulator-mandated formula.

Define “enrolled” against the protocol and registry requirements. ClinicalTrials.gov’s enrollment definition should not automatically be treated as randomization. Track consent, screening, enrollment, randomization and first dose as separate milestones where applicable. Also report activation-to-first-participant time and the distribution of site results, so a pooled average does not hide a small number of productive centers. [2]

Before forecasting a new study, compare indications, molecular selection, prior-treatment requirements, visit burden, country mix and competing studies. These factors are review questions; the sponsor ranking itself does not quantify their contribution or establish a causal advantage.

What this means for oncology and equitable access

Cancer trials were deliberately excluded from the ranking. These non-cancer values do not establish a target for a biomarker-selected oncology protocol. In a cancer study, an operations team could examine whether a patient is lost while tissue is requested, eligibility is confirmed or baseline assessments are scheduled. Those are proposed checks rather than findings about the sponsors in the chart.

Recruitment performance also needs a representation check. FDA’s final December 2025 participation guidance recommends approaches to enrolling populations that better reflect the people who may use a drug. A high aggregate rate alone does not establish representative access. Review referral sources and participation barriers alongside enrollment, and interpret subgroup counts in the context of the intended population. [3]

Selecting only the easiest-to-reach sites could improve an aggregate metric while narrowing geographic reach. That is a planning tradeoff to evaluate, not a result demonstrated by this ranking. Adding a community site may be appropriate for access or scientific reasons even when it does not immediately maximize a pooled enrollment rate.

What this means for trial teams

Start with a verified observation. Reconcile the site’s recruitment-open dates, screening records and relevant participant milestones. An oncology CRA can check documentation and escalate recurring delays through the monitoring plan.

Match the response to the constraint. Additional sites may address insufficient reach. A shared laboratory or records delay calls for a different review. Any change to eligibility or required procedures needs the appropriate sponsor, investigator, regulatory and ethics processes. Staffing alone cannot remove protocol-defined exclusions.

Name the owner and verify the next result. Use the relevant parts of Lampgen’s SIGNAL™ framework—Spot, Investigate, Gauge, Name, Act and Learn—to connect the observed delay to an accountable response. Review whether the action changed time to the next milestone, while retaining safety, data quality and representation checks. These are Lampgen’s recommendations, not validated results of the sponsor ranking.

Use the ranking to prompt investigation. The practical benefit is a more defensible forecast and a better-targeted response to enrollment shortfalls. Neither cost savings nor a shorter development timeline can be calculated from these figures alone. Lampgen Clinical Research provides oncology CRA staffing and clinical-operations support around this work.

Analysis by Tommy Lampley, Jr., M.S., Founder, Lampgen Clinical Research. Published November 12, 2026.

Sources

  1. 1. Bond Health LinkedIn analysis, November 2026; figures and method reviewed from user-supplied screenshots. Link is the publisher’s profile, not a recovered post or underlying dataset.
  2. 2. ClinicalTrials.gov FAQ: enrollment, study start and primary completion definitions
  3. 3. FDA, Enhancing Participation in Clinical Trials—Eligibility Criteria, Enrollment Practices, and Trial Designs, final guidance, December 2025
  4. Related Lampgen insight: screen-failure review before adding sites
  5. Related Lampgen insight: participation burden and patient access
  6. Lampgen oncology CRA staffing

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?